CN109055527A - For detecting the primed probe group and its application of rs4149056 - Google Patents
For detecting the primed probe group and its application of rs4149056 Download PDFInfo
- Publication number
- CN109055527A CN109055527A CN201810954012.6A CN201810954012A CN109055527A CN 109055527 A CN109055527 A CN 109055527A CN 201810954012 A CN201810954012 A CN 201810954012A CN 109055527 A CN109055527 A CN 109055527A
- Authority
- CN
- China
- Prior art keywords
- sequence
- component
- probe
- nucleotide
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of for detecting the primed probe group and its application of rs4149056.The present invention protects a kind of primed probe group first, is made of primers F, primer R and probe P；Primers F is single strand dna shown in the sequence 1 of sequence table；Primer R is single strand dna shown in the sequence 2 of sequence table；Probe P is the single strand dna that an end has fluorescent quenching group with fluorophor and another end, and the partial nucleotide in DNA molecular is lock nucleic acid, and the nucleotides sequence of DNA molecular is classified as shown in the sequence 3 of sequence table.The present invention can be used for detecting rs4149056, judge genotype of the sample to be tested based on the site, to instruct to use medication, have great application and popularization value.
Description
Technical field
The present invention relates to a kind of for detecting the primed probe group and its application of rs4149056.
Background technique
SLCO1B1 gene encodes organic anion and transports polypeptide OATP1B1, and OATP1B1 is transmembrane transporter, mainly
It is distributed in liver, there is the physiological function for mediating liver plasma membrane to transport inside and outside source property substance and be metabolized and eliminated to it,
Important regulating and controlling effect is played in the drugs such as transhipment Statins, antidiabetic drug, rifampin, angiotensinⅡ, receptor antagonist.Closely
It has been found successively on Nian Lai, SLC01B1 gene multiple mononucleotide polymorphism sites (SNP), some of them SNP is in vitro
Or it is confirmed in experiment in vivo closely related with transport function.
Test confirms that 521 T of SLC01B1 > C gene mutation will lead to the Clnr of lipid-lowering statins Pravastatin
It reduces, blood concentration increases, and the occurrence frequency in tool report 521 T > C Japanese population is about 15.8%, prominent in Chinese population
Becoming occurrence frequency is about 14%, close with Japan, and there may be similar incidences in the crowd of east for prompt.Research is also shown
521 T of SLCO1B1 > C gene pleiomorphism is a key factor for influencing blood plasma basis bilirubin level, 521 T > C mutation
The effect that carrier's Pravastatin reduces total cholesterol is obviously reduced compared with wild-type homozygote carrier.
For 521 T > site C, heterozygous mutation and no mutant homozygote account for the 24.1% and 1.96% of total number of persons respectively, wild
Type homozygote accounts for the 73.9% of total number of persons.When SLCO1B1 gene mutates, transport function decline can seriously affect liver
Absorption of drugs, the statins concentration that will lead in blood rise, and increase adverse reaction (such as rhabdomyolysis of drug
Disease etc.), and then influence therapeutic effect.The mutation for checking allele 521T > C of SLCO1B1 can be clinician to disease
Diagnosis and medical treatment provide important medication foundation.
Summary of the invention
The object of the present invention is to provide a kind of for detecting the primed probe group and its application of rs4149056.
The present invention protects a kind of primed probe group first, is made of primers F, primer R and probe P；
Primers F is following (a1) or (a2):
(a1) single strand dna shown in the sequence 1 of sequence table；
(a2) have by sequence 1 by the substitution and/or deletion and/or addition of one or several nucleotide and with sequence 1 identical
The DNA molecular of function；
Primer R is following (b1) or (b2):
(b1) single strand dna shown in the sequence 2 of sequence table；
(b2) have by sequence 2 by the substitution and/or deletion and/or addition of one or several nucleotide and with sequence 2 identical
The DNA molecular of function；
Probe P is the single strand dna that an end has fluorescent quenching group with fluorophor and another end, and
Partial nucleotide in DNA molecular is lock nucleic acid, and the nucleotides sequence of DNA molecular is classified as following (c1) or (c2):
(c1) shown in the sequence 3 of sequence table；
(c2) by sequence 3 by the substitution and/or deletion and/or addition of one or several nucleotide.
Probe P is 5 ' ends with FAM fluorophor and 3 ' ends have the single stranded DNA point of BHQ1 fluorescent quenching group
Son.
Specifically, the nucleotide sequence of the probe P is as shown in the sequence 3 of sequence table, and 1-3 nucleotide and
24-26 nucleotide are lock nucleic acid.
In the primed probe group, the mol ratio of primers F, primer R, probe P are as follows: 2.5:15:15.
The present invention also protects the primed probe group preparing the application in the kit for detecting rs4149056.
The present invention also protects a kind of for detecting the kit of rs4149056, including the primed probe group.
The present invention also protects component first and component second preparing the application in the kit for detecting rs4149056；Group
Part first is the primed probe group；Component second is that reagent or reagent combine, and the function of component second is to be used for blood sample preparation
The template samples of quantitative fluorescent PCR.Component second includes lysate.The lysate is the NaCl aqueous solution of 1.5-2 g/100ml,
The concretely NaCl aqueous solution of 1.7 g/100ml.Component second further includes saving liquid.Save the preparation method of liquid: 1. by 25 bodies
Product part FG buffer and the mixing of 4 parts by volume Proteinase K Solutions, obtain mixed liquor；2. 1. mixed liquor that 1 parts by volume step is obtained
With 5 parts by volume ddH2O mixing obtains saving liquid.
The present invention also protects a kind of for detecting the kit of rs4149056, including component first and component second；Component first is
The primed probe group；Component second is that reagent or reagent combine, and the function of component second is fixed for fluorescence with blood sample preparation
Measure the template samples of PCR.Component second includes lysate.The lysate is the NaCl aqueous solution of 1.5-2 g/100ml, specifically may be used
For the NaCl aqueous solution of 1.7 g/100ml.Component second further includes saving liquid.Save the preparation method of liquid: 1. by 25 parts by volume FG
Buffer and the mixing of 4 parts by volume Proteinase K Solutions, obtain mixed liquor；2. 1. mixed liquor and 5 bodies that 1 parts by volume step is obtained
Product part ddH2O mixing obtains saving liquid.
The present invention also protects a kind of kit, including lysate.The function of the kit is with blood sample preparation for glimmering
The template samples of Fluorescent Quantitative PCR.The lysate is the NaCl aqueous solution of 1.5-2 g/100ml, concretely 1.7 g/100ml
NaCl aqueous solution.The kit further includes saving liquid.Save the preparation method of liquid: 1. by 25 parts by volume FG buffers and 4
The mixing of parts by volume Proteinase K Solution, obtains mixed liquor；2. 1. mixed liquor and 5 parts by volume ddH that 1 parts by volume step is obtained2O
Mixing obtains saving liquid.
A kind of method that the present invention also protects template samples with blood sample preparation for quantitative fluorescent PCR, including such as
Lower step:
(1) anticoagulation is taken, the lysate is added, is mixed by inversion, supernatant is abandoned in centrifugation；
(2) after completing step (1), the preservation liquid, 60-70 DEG C first (concretely 65 DEG C) water-bath, then 80-90 DEG C of (tool is added
Body can be 85 DEG C) water-bath, it is then centrifuged for, when use takes supernatant, as template samples.
The method of the template samples with blood sample preparation for quantitative fluorescent PCR, specifically comprises the following steps:
(1) 65 μ L EDTA anticoagulations are taken, lysate described in 500 μ L of addition is mixed by inversion, 12000rpm centrifugation 4min, in abandoning
Clearly；
(2) it after completing step (1), is added and saves liquid described in 120 μ L, first 65 DEG C of water-bath 10min, then 85 DEG C of water-bath 10min, then
12000rpm is centrifuged 4min, is subsequently placed in 4 DEG C and saves backup, and when use takes supernatant, as template samples.
The present invention also protects specific probe carrying out the application in fluorescence quantitative PCR detection；The specific probe be with
The molecular beacon of lock nucleic acid modification.
The present invention also protects a kind of specific probe for fluorescence quantitative PCR detection, for the molecule modified with lock nucleic acid
Beacon.
Any description above rs4149056 is the 56th core of nucleotide shown in the sequence 4 of sequence table in human gene group DNA
Thuja acid.
Nucleosides shown in sequence 4 of any description above rs4149056 for sequence table in the OATP1B1 gene in human genome
33rd nucleotide of acid.
The present invention is directed to detect the Genotyping of most important mononucleotide polymorphism site in OATP1B1 gene, determine
The drug metabolic rate type of patient, to help doctor correctly to select drug and reasonably adjust drug dose, improving drug makes
With validity, and reduce toxic side effect.
Primed probe group provided by the invention using molecular beacon as probe, and introduces several lock nucleic acids.Molecule
Beacon is a kind of fluorescence probe, by ring-shaped area and stem district's groups at the 5' end mark fluorophor in stem area, the end 3' is marked
Remember quencher, is in hairpin structure when closure, the fluorescence that fluorophor issues is quenched group absorptions, whole not issue fluorescence letter
Number.In the presence of target sequence, in conjunction with target sequence, stem part is forced to open ring portion, fluorophor far from quenching group,
Issue fluorescence.Δ Tm value very little between nucleotide chain with mononucleotide difference, general detection means are difficult to differentiate between.Lock nucleic acid
It is a kind of double-ring oligonucleotide derivative, base pair complementarity principle can be followed in conjunction with nucleic acid, the β-D- in structure
2'-O and 4'-C of ribofuranose act on forming Oxymethylene bridge, sulphur methylene bridge or amine methylene bridge by shrink, and even
It is connected into annular, this annular bridge has locked the N configuration of furanose C3'- inner mold, reduces the flexibility of ribose structure, increases
The stability of phosphate backbone partial structurtes.In LNA/DNA heteroduplex, one LNA monomer of every increase, Tm improves 2-6 DEG C.
The application method of primed probe group provided by the invention: template samples are prepared with blood sample, then use primer
Probe groups carry out unbalanced fluorescent quantitative PCR, judge genotype by observing melting curve.Imbalance amplification: it is added
The excessive and reversed primer of probe, a small amount of primer in the same direction with probe and suitable probe P, after amplification, due to
Side primer is present in excess, and the template strand that participation amplification obtains is extra far more than the chain obtained with other side primer amplification
The not formed double-strand of template strand, the individualism in system.
The method of template samples provided by the invention with blood sample preparation for quantitative fluorescent PCR, it is easy to operate,
Product may be implemented to carry out effective fluorescent quantitative PCR as template.
Provided by the present invention for the specific probe of fluorescence quantitative PCR detection, for the molecular beacon modified with lock nucleic acid.
The Tm value of nucleotide combination double-strand can be significantly improved due to introducing lock nucleic acid.By controlling the temperature change of melting curve,
To control the closure of molecular beacon, analyzes to obtain fluorescence curve by data and change corresponding peak value map and distinguish open country well
The mutation chain of raw chain and unit point.In addition, will appear two peaks in the peak value map of melting curve for heterozygous sample
Value, avoids general PCR and expands the cumbersome of definitive result twice.
The present invention can be used for detecting rs4149056, judge genotype of the sample to be tested based on the site, to instruct with use
Medicine has great application and popularization value.
Detailed description of the invention
Fig. 1 is the melting curve of exemplary sample (TT is homozygous).
Fig. 2 is the melting curve of exemplary sample (CC is homozygous).
Fig. 3 is the melting curve (CT heterozygous) of exemplary sample.
Fig. 4 is the melting curve of exemplary sample (TT is homozygous).
Fig. 5 is the melting curve of exemplary sample (CC is homozygous).
Fig. 6 is the melting curve (CT heterozygous) of exemplary sample.
Fig. 7 is the melting curve of exemplary sample (TT is homozygous).
Fig. 8 is the melting curve of exemplary sample (CC is homozygous).
Fig. 9 is the melting curve (CT heterozygous) of exemplary sample.
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method is unless otherwise specified conventional method.Test material as used in the following examples is unless otherwise specified certainly
What routine biochemistry reagent shop was commercially available.Quantitative test in following embodiment is respectively provided with three repeated experiments, as a result makes even
Mean value.Unless otherwise specified, each nucleotide in primer, probe and target sequence is the nucleotide on conventional meaning.
Embodiment 1, the design of primed probe group for detecting rs4149056
By largely designing, preliminary experiment, effect compare, obtain one group for detecting the primed probe group of rs4149056.
Primers F: 5'- AAAGGAATCTGGGTCATACATGTGGA-3'；
Primer R:5'-TTAGCGAAATCATCAATGTAAGAAAG-3'；
Probe P:5'-FAM-TGCGTTCATGGGTAATATGCTTCGCA-BHQ1-3'。
Primers F is single strand dna shown in the sequence 1 of sequence table.Primer R is single-stranded shown in the sequence 2 of sequence table
DNA molecular.Probe P is 5 ' ends with FAM fluorophor and 3 ' ends have the single stranded DNA point of BHQ1 fluorescent quenching group
Son, the nucleotide sequence of DNA molecular is as shown in the sequence 3 of sequence table, nucleotide (i.e. the 1st, the 2nd, the of underscore mark
3, the 24th, the 25th and the 26th) it is lock nucleic acid (LNA).
The target sequence of primers F and primer R are as shown in the sequence 4 of sequence table.
The application of embodiment 2, primed probe group for detecting rs4149056
One, blood sample processing (processing method of single blood sample)
1,65 μ L EDTA anticoagulations are taken, 500 μ L lysates are added, are mixed by inversion, 12000rpm is centrifuged 4min, abandons supernatant.
Lysate are as follows: 1.7g/100ml NaCl aqueous solution.
2, after completing step 1,120 μ L is added and save liquid, first 65 DEG C of water-bath 10min, then 85 DEG C of water-bath 10min, then
12000rpm is centrifuged 4min, is subsequently placed in 4 DEG C and saves backup, and when use takes supernatant, as template samples.
It saves the preparation method of liquid: 1. 25 parts by volume FG buffers and 4 parts by volume Proteinase K Solutions being mixed, are mixed
Close liquid；2. 1. mixed liquor and 5 parts by volume ddH that 1 parts by volume step is obtained2O mixing obtains saving liquid.
FG buffer: the Buffer FG in poba gene group DNA extraction system (0.1-20ml) (DP319) kit.Egg
White enzyme K solution: the Proteinase K in poba gene group DNA extraction system (0.1-20ml) (DP319) kit, concentration are
20mg/ml.The producer of poba gene group DNA extraction system (0.1-20ml) (DP319) is that Tiangeng biochemical technology (Beijing) is limited
Company.
Two, the amplification of PCR and the acquisition of fluorescence signal
1, it takes EP to manage, each component is added, prepare reaction system.
Reaction system: 7.5 μ L 2 × Reaction Buffer, 0.12 μ L Taq archaeal dna polymerase solution (Taq containing 0.6U
Archaeal dna polymerase), 0.09 μ L dNTP solution (in dNTP solution contain dATP, dCTP and dGTP, dATP, dCTP and dGTP exist
Concentration in dNTP solution is 33mmol/L), (in dUTP solution, the concentration of dUTP is 100mmol/ to 0.06 μ L dUTP solution
L), 0.06 μ L UDG enzyme solutions (enzyme of UDG containing 0.12U), 3 μ L 5 × PCR Enhancer, 0.3 μ L primers F solution, 0.3 μ L draw
DdH2O to 15 μ L is added in the template samples that object R solution, 0.3 μ L probe P solution, 1 μ L step 1 obtain.In reaction system, draw
The concentration of object F is 2.5 μM, and the concentration of primer R is 15 μM, and the concentration of probe P is 15 μM.
Buffer: Fei Peng Biological Co., Ltd. of 2 × Reaction.Taq archaeal dna polymerase solution, that is, AnstartTaq
DNA Polymerase, 5U/ μ L, Fei Peng Biological Co., Ltd..UDG enzyme solutions, that is, Uracil-DNA Glycosylase,
2U/ μ L, Fei Peng Biological Co., Ltd..5 × PCR Enhancer: Tiangeng biochemical technology Co., Ltd, article No. RP202.
2, the EP pipe for taking into step 1, is added 25 μ L paraffin.
3, the EP pipe for taking into step 2, carries out quantitative fluorescent PCR.
①50℃ 2min,95℃ 10min；
2. 95 DEG C of 15s, 55 DEG C of 15s, 72 DEG C of 20s, 50 circulations；
③95℃ 5min,20℃ 5min；45 DEG C of 1s, it is then heated up for interval up to 75 DEG C (every since 45 DEG C with 0.3 DEG C
A temperature acquisition fluorescence obtains melting curve) and then 75 DEG C of 15s.
If being shown as unimodal in melting curve, and the corresponding Tm value of peak value is 52.60 DEG C -54.00 DEG C, sample is based on
The genotype of rs4149056 is that TT is homozygous.
If being shown as unimodal in melting curve, and the corresponding Tm value of peak value is 59.00 DEG C -58.45 DEG C, sample is based on
The genotype of rs4149056 is that CC is homozygous.
If being shown as bimodal in melting curve, and the peak value at two peaks respectively corresponds 52.60 DEG C -54.00 DEG C and 59.00
DEG C -58.45 DEG C, genotype of the sample based on rs4149056 is CT heterozygous.
It to volunteer's EDTA anticoagulation of 500 informed consents, is then detected according to above-mentioned steps, 7 will
The genotype of hope person is that CC is homozygous, genotype of 366 volunteers are that TT is homozygous, genotype of 127 volunteers are CT
Heterozygous.It extracts the anticoagulant genomic DNA of EDTA and carries out sequence verification, sequencing result shows the standard of above-mentioned steps identification
True rate is 100%.
In volunteer's EDTA anticoagulation of 500 informed consents, the result is shown in Figure 1s of 3 exemplary samples, Fig. 2 and
Fig. 3.It is shown as unimodal in the melting curve of exemplary sample in Fig. 1, the corresponding Tm value of peak value is 53.35 DEG C, the volunteer's
Genotype is that TT is homozygous.It is shown as unimodal in the melting curve of exemplary sample in Fig. 2, the corresponding Tm value of peak value is 59.75
DEG C, the genotype of the volunteer is that CC is homozygous.It is shown as bimodal in the melting curve of exemplary sample in Fig. 3, peak value is corresponding
Tm value be respectively 53.35 DEG C and 59.75 DEG C, the genotype of the volunteer is CT heterozygous.
Comparative example 1,
One, blood sample is handled
With the step of embodiment 2 one.
Two, the amplification of PCR and the acquisition of fluorescence signal
1, it takes EP to manage, each component is added, prepare reaction system.
Replace probe P with probe DP, other with the step of embodiment 2 two 1.
Probe DP:5'-FAM- TGCGTTCATGGGTAATATGCTTCGCA-BHQ1-3'.
2, the EP pipe for taking into step 1, is added 25 μ L paraffin.
3, the EP pipe for taking into step 2, carries out quantitative fluorescent PCR.
Response procedures with the step of embodiment 2 one 3.
To 500 parts of EDTA anticoagulations in embodiment 2, then detected according to above-mentioned steps.
The sample standard deviation of each genotype is shown without effective peak.
The result of 3 exemplary samples is shown in Fig. 4 (TT is homozygous), Fig. 5 (CC is homozygous) and Fig. 6 (CT heterozygous).
Comparative example 2,
One, blood sample is handled
With the step of embodiment 2 one.
Two, the amplification of PCR and the acquisition of fluorescence signal
1, it takes EP to manage, each component is added, prepare reaction system.
Replace primers F with primer DF, and replace primer R with primer DR, other with the step of embodiment 2 two 1.
DF:5'- AAGGAATCTGGGTCATACATGTGGAT -3'；
DR:5'- TAGCGAAATCATCAATGTAAGAAAGC -3'.
2, the EP pipe for taking into step 1, is added 25 μ L paraffin.
3, the EP pipe for taking into step 2, carries out quantitative fluorescent PCR.
Response procedures with the step of embodiment 2 one 3.
To 500 parts of EDTA anticoagulations in embodiment 2, then detected according to above-mentioned steps.
The sample standard deviation of each genotype is shown without effective peak.
The result of 3 exemplary samples is shown in Fig. 7 (TT is homozygous), Fig. 8 (CC is homozygous) and Fig. 9 (CT heterozygous).
Sequence table
<110>Weifang De-Nol Tyke Biotechnology Co., Ltd
<120>for detecting the primed probe group and its application of rs4149056
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 26
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
aaaggaatct gggtcataca tgtgga 26
<210> 2
<211> 26
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
ttagcgaaat catcaatgta agaaag 26
<210> 3
<211> 26
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
tgcgttcatg ggtaatatgc ttcgca 26
<210> 4
<211> 114
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (56)
<223> y =t or c
<400> 4
aaaggaatct gggtcataca tgtggatata tgygttcatg ggtaatatgc ttcgtggaat 60
aggggagact cccatagtac cattggggct ttcttacatt gatgatttcg ctaa 114
Claims (10)
1. primed probe group is made of primers F, primer R and probe P；
Primers F is following (a1) or (a2):
(a1) single strand dna shown in the sequence 1 of sequence table；
(a2) have by sequence 1 by the substitution and/or deletion and/or addition of one or several nucleotide and with sequence 1 identical
The DNA molecular of function；
Primer R is following (b1) or (b2):
(b1) single strand dna shown in the sequence 2 of sequence table；
(b2) have by sequence 2 by the substitution and/or deletion and/or addition of one or several nucleotide and with sequence 2 identical
The DNA molecular of function；
Probe P is the single strand dna that an end has fluorescent quenching group with fluorophor and another end, and
Partial nucleotide in DNA molecular is lock nucleic acid, and the nucleotides sequence of DNA molecular is classified as following (c1) or (c2):
(c1) shown in the sequence 3 of sequence table；
(c2) by sequence 3 by the substitution and/or deletion and/or addition of one or several nucleotide.
2. primed probe group as described in claim 1, it is characterised in that: the nucleotide sequence such as sequence table of the probe P
Shown in sequence 3, and 1-3 nucleotide and 24-26 nucleotide are lock nucleic acid.
3. primed probe group as claimed in claim 1 or 2 is preparing the application in the kit for detecting rs4149056.
4. a kind of for detecting the kit of rs4149056, including primed probe group as claimed in claim 1 or 2.
5. component first and component second are preparing the application in the kit for detecting rs4149056；Component first is claim 1
Or 2 primed probe group；Component second is that reagent or reagent combine, and the function of component second is to be used for fluorescence with blood sample preparation
The template samples of quantitative PCR.
6. a kind of for detecting the kit of rs4149056, including component first and component second；Component first is claims 1 or 2 institute
State primed probe group；Component second is that reagent or reagent combine, and the function of component second is to be used for fluorescent quantitation with blood sample preparation
The template samples of PCR.
7. a kind of kit of the template samples with blood sample preparation for quantitative fluorescent PCR, including lysate；The cracking
Liquid is the NaCl aqueous solution that the lysate is 1.5-2 g/100ml.
8. a kind of method of the template samples with blood sample preparation for quantitative fluorescent PCR, includes the following steps:
(1) anticoagulation is taken, lysate described in claim 7 is added, is mixed by inversion, supernatant is abandoned in centrifugation；
(2) it after completing step (1), is added and saves liquid, first 60-70 DEG C of water-bath, then 80-90 DEG C of water-bath is then centrifuged for, and when use takes
Supernatant, as template samples.
9. specific probe is carrying out the application in fluorescence quantitative PCR detection；The specific probe is point modified with lock nucleic acid
Sub- beacon.
10. a kind of specific probe for fluorescence quantitative PCR detection, for the molecular beacon modified with lock nucleic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810954012.6A CN109055527A (en) | 2018-08-21 | 2018-08-21 | For detecting the primed probe group and its application of rs4149056 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810954012.6A CN109055527A (en) | 2018-08-21 | 2018-08-21 | For detecting the primed probe group and its application of rs4149056 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109055527A true CN109055527A (en) | 2018-12-21 |
Family
ID=64687647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810954012.6A Pending CN109055527A (en) | 2018-08-21 | 2018-08-21 | For detecting the primed probe group and its application of rs4149056 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109055527A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013056087A2 (en) * | 2011-10-13 | 2013-04-18 | Boston Heart Diagnostics | Compositions and methods for treating and preventing coronary heart disease |
| WO2014181107A1 (en) * | 2013-05-09 | 2014-11-13 | Medical Research Council | Genetic method of aiding the diagnosis and treatment of familial hypercholersterolaemia |
| CN105255863A (en) * | 2015-10-10 | 2016-01-20 | 北京晋祺生物科技有限公司 | Detection primers and compound of SLCO1B1521T>C |
| CN106987618A (en) * | 2016-01-21 | 2017-07-28 | 张培祥 | The multiple gene mononucleotide polymorphism Sites Combinations related to statins personalized medicine and its application |
| CN108060230A (en) * | 2018-02-07 | 2018-05-22 | 山东德诺生物科技有限公司 | For detecting the primed probe group of rs1045642 and its application |
| CN108315397A (en) * | 2018-04-08 | 2018-07-24 | 南昌艾迪康医学检验实验室有限公司 | Detect method, primer and the kit of SLCO1B1 gene mutations |
-
2018
- 2018-08-21 CN CN201810954012.6A patent/CN109055527A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013056087A2 (en) * | 2011-10-13 | 2013-04-18 | Boston Heart Diagnostics | Compositions and methods for treating and preventing coronary heart disease |
| WO2014181107A1 (en) * | 2013-05-09 | 2014-11-13 | Medical Research Council | Genetic method of aiding the diagnosis and treatment of familial hypercholersterolaemia |
| CN105255863A (en) * | 2015-10-10 | 2016-01-20 | 北京晋祺生物科技有限公司 | Detection primers and compound of SLCO1B1521T>C |
| CN106987618A (en) * | 2016-01-21 | 2017-07-28 | 张培祥 | The multiple gene mononucleotide polymorphism Sites Combinations related to statins personalized medicine and its application |
| CN108060230A (en) * | 2018-02-07 | 2018-05-22 | 山东德诺生物科技有限公司 | For detecting the primed probe group of rs1045642 and its application |
| CN108315397A (en) * | 2018-04-08 | 2018-07-24 | 南昌艾迪康医学检验实验室有限公司 | Detect method, primer and the kit of SLCO1B1 gene mutations |
Non-Patent Citations (3)
| Title |
|---|
| ELENI AKLILLU等: "Frequency of the SLCO1 B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method", 《EUR J CLIN PHARMACOL》 * |
| HIROKO FUKUSHIMA等: "Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies", 《LEUKEMIA RESEARCH AND TREATMENT》 * |
| PAULO CJL SAN TOS等: "SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group", 《BMC MEDICAL GENETICS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108060230A (en) | For detecting the primed probe group of rs1045642 and its application | |
| KR101153058B1 (en) | Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same | |
| EP2551356B1 (en) | Method for detecting target base sequence using competitive primer | |
| KR20100080621A (en) | Method for amplification of target nucleic acid sequence, method for detection of mutation by using the method, and reagents for use in the methods | |
| WO2012033190A1 (en) | Method for inhibiting nucleic acid amplification using light and highly sensitive method for selective nucleic acid amplification | |
| CN106086192A (en) | The parting detecting reagent of tacrolimus personalized medicine related gene | |
| KR20080100429A (en) | Primer set for amplification of cyp2c19 gene, reagent for amplification of cyp2c19 gene comprising the same, and use of the same | |
| CN112852933A (en) | Kit and method for detecting CYP2C19 gene polymorphism by RMA (reduced Raman amplification) method based on locked nucleic acid modification | |
| CN102666852A (en) | Primer set for amplification of MTHFR gene, MTHFR gene amplification reagent comprising same, and use of same | |
| EP2025764B1 (en) | Probe for detection of mutation in abl gene and use thereof | |
| EP2450443B1 (en) | Target sequence amplification method, polymorphism detection method, and reagents for use in the methods | |
| EP2013366B1 (en) | Sequencing of the L10 codon of the HIV gag gene | |
| JP6153515B2 (en) | Method for detecting HLA-A * 24: 02 and detection kit | |
| CN109055527A (en) | For detecting the primed probe group and its application of rs4149056 | |
| CN108949964A (en) | For detecting the primed probe group and its application of rs12041331 | |
| CN108949966A (en) | For detecting the primed probe group and its application of rs1801133 | |
| CN113981069A (en) | Primer and kit for detecting ADRB1 gene G1165C polymorphism, detection method and application thereof | |
| CN109371019A (en) | For detecting the primed probe group and its application of rs6065 | |
| CN109022430A (en) | For detecting the primed probe group and its application of rs730012 | |
| CN108929913A (en) | For detecting the primed probe group and its application of rs2032582 | |
| KR20150102455A (en) | Ultra High Sensitive Method for Amplification of mutant DNA and primer thereof | |
| CN109055526A (en) | For detecting the primed probe group and its application of rs662 | |
| CN108949996A (en) | For detecting the primed probe group and its application of rs1695 | |
| CN109371115A (en) | For detecting the primed probe group and its application of rs5918 | |
| CN112695083B (en) | Nucleic acid composition and kit for detecting gene polymorphism of medicine for hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181221 |